ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial.

e14129Background: ASN001 is a novel non-steroidal CYP17 lyase inhibitor. In preclinical studies, ASN001 shows potent inhibition of CYP17 lyase with selective inhibition of testosterone synthesis ov...